Targeted therapy in advanced colorectal cancer, an update

ArticleinTargeted Oncology 2(3):165-172 · July 2007with4 Reads
Impact Factor: 4.00 · DOI: 10.1007/s11523-007-0052-7

    Abstract

    The introduction of inhibitors of signal transduction pathways has increased the therapeutic arsenal for patients with advanced
    colorectal cancer (ACC). Bevacizumab, a monoclonal vascular endothelial growth factor antibody, is currently part of the standard
    first-line treatment in combination with fluoropyrimidine-based chemotherapy. Cetuximab, a chimeric monoclonal antibody against
    the epidermal growth factor receptor, has shown efficacy in irinotecan-refractory ACC patients. Several experimental targeted
    agents, including small molecules that inhibit receptor tyrosine kinase activity, are currently being tested. We review the
    mechanism of action as well as the current status of targeted therapy in ACC.